The National Association of Pharmaceutical Laboratories (ALAFARPE) has officially announced the appointment of its new Board of Directors for the 2026–2027 term. Stepping into the role of President is María Julia Caffaro, the current General Manager of Roche Farma Perú. Her appointment marks a significant transition for the organization, which serves as the primary representative body for the leading national and multinational pharmaceutical companies operating within the Peruvian healthcare ecosystem.
Caffaro, a distinguished leader in the life sciences sector, takes the helm at a critical juncture for Peru’s healthcare system. Her leadership is expected to focus on bridging the gap between cutting-edge medical innovation and patient accessibility, a cornerstone of her professional philosophy.
The New Leadership: Profile of María Julia Caffaro
María Julia Caffaro brings a unique blend of clinical expertise and executive acumen to ALAFARPE. A medical doctor by training, she specializes in hematology—a discipline recognized by the Argentine Society of Hematology. Her academic foundation was established at the prestigious University of Buenos Aires, providing her with the deep scientific literacy required to navigate the complexities of modern pharmaceutical development.
Beyond her clinical credentials, Caffaro has bolstered her profile with executive training from the IAE Business School. This combination of medical rigor and strategic management allows her to translate complex therapeutic advancements into actionable business and public health policies. Her tenure at Roche Farma Perú has been characterized by a focus on personalized healthcare, a vision she now aims to scale across the broader industry through her leadership at ALAFARPE.
Chronology of Institutional Governance
To understand the weight of this transition, it is essential to look at the recent trajectory of ALAFARPE.
- 1953: Foundation of ALAFARPE, establishing a collective voice for pharmaceutical entities in Peru.
- 2024–2025: Under the leadership of outgoing President Diego Hovispo (General Manager of Sanofi Perú), the association prioritized structured dialogues between the public and private sectors. This period was marked by successful lobbying efforts to streamline the regulatory approval process for new therapies.
- January 2026: Official transition of the Board of Directors. Diego Hovispo steps down as President but maintains an active role in the association’s continuity, transitioning into the position of Vice President.
- 2026–2027 Term: María Julia Caffaro assumes the presidency, tasked with accelerating the initiatives set forth by her predecessor while introducing new strategic goals focused on digital health and patient-centric policy reform.
The Strategic Agenda: Official Responses and Vision
In her acceptance remarks, Caffaro emphasized that her leadership would not merely be administrative but deeply mission-driven. "I assume this responsibility with the commitment to continue promoting an agenda that allows health innovation to reach patients in a timely manner," she stated.
Caffaro’s vision for the next two years is built upon three pillars:
- Evidence-Based Decision Making: Ensuring that public health policy in Peru is guided by robust data, clinical outcomes, and global best practices.
- Process Agility: Reducing the bureaucratic hurdles that often delay the entry of life-saving medicines into the Peruvian market.
- Sustainable Access: Creating economic and regulatory frameworks that ensure high-quality, innovative treatments are not just available, but affordable and accessible to the broader population.
"From ALAFARPE, we want to continue contributing to the strengthening of a health system that promotes more agile processes and guarantees sustainable access to innovative medicines," Caffaro added.
ALAFARPE: An Overview of the Ecosystem
Founded in 1953, ALAFARPE has spent over seven decades positioning itself as the voice of the pharmaceutical industry in Peru. Its composition reflects the globalized nature of modern medicine, bringing together diverse players to address local challenges.
The association currently represents:
- 21 Pharmaceutical Laboratories: A mix of national and multinational firms committed to the R&D and distribution of safe, effective, and quality-assured medications.
- 6 Medical Device Companies: Reflecting the industry’s expansion into integrated healthcare solutions.
- 3 Strategic Allies: Partners that provide the logistical and technological infrastructure necessary for the health sector to function.
This coalition represents the backbone of Peru’s pharmaceutical supply chain. The diversity of its members allows ALAFARPE to advocate for policies that benefit not just the industry, but the entire patient journey—from diagnosis to treatment and long-term care.
Implications for the Peruvian Healthcare Sector
The appointment of a new Board of Directors carries significant implications for the future of the Peruvian healthcare landscape.
1. The Push for Regulatory Reform
The primary challenge facing the industry in Peru remains the "time-to-patient" metric. Currently, the approval cycles for new molecules and medical devices can be protracted. Under Caffaro’s leadership, the association is expected to intensify its collaboration with the General Directorate of Medicines, Supplies and Drugs (DIGEMID) and other health authorities to digitize approval workflows and harmonize local requirements with international standards.
2. Bridging the Public-Private Divide
The successful legacy of the 2024–2025 term established a foundation of trust between private laboratories and government health providers. The continuity provided by Diego Hovispo’s transition to Vice President ensures that these collaborative efforts will not lose momentum. This "continuity of purpose" is vital for long-term health planning, particularly as Peru looks to expand universal health coverage.
3. Innovation and Personalized Medicine
With a President whose background is rooted in hematology—a field that has seen some of the most significant breakthroughs in oncology and precision medicine—it is highly probable that ALAFARPE will place a greater emphasis on the introduction of "orphan drugs" and targeted therapies in Peru. This shift could potentially transform the standard of care for patients suffering from rare and chronic diseases.
4. Economic Sustainability
The pharmaceutical sector is not immune to the inflationary pressures and supply chain volatility that have impacted the global economy. ALAFARPE’s new leadership will likely focus on advocating for fiscal policies that encourage local investment while ensuring that public procurement programs (such as those managed by EsSalud and SIS) remain financially viable.
Future Outlook: A Holistic Approach to Health
As ALAFARPE moves into the 2026–2027 period, the industry faces a complex environment characterized by rapid technological change, an aging population, and an increasing demand for high-cost specialized treatments.
The transition from Diego Hovispo to María Julia Caffaro is a symbolic and strategic move. It signals a shift toward a leadership style that is as much about scientific advocacy as it is about regulatory negotiation. By integrating her experience in hematology with her executive management skills, Caffaro is uniquely positioned to lead the association toward its goal of making Peru a regional hub for healthcare innovation.
The coming months will be telling. Stakeholders in the Peruvian health sector—including patient advocacy groups, government regulators, and international observers—will be watching to see how the new Board of Directors navigates the tension between market accessibility and fiscal constraints.
Ultimately, the mission of ALAFARPE remains clear: to ensure that the patient is the beneficiary of every policy, every innovation, and every collaborative effort. Under the guidance of María Julia Caffaro, the association is set to build upon its legacy, ensuring that the pharmaceutical industry remains a pillar of national development and a guarantor of public health.
Conclusion
The election of the new ALAFARPE Board of Directors is more than a change in personnel; it is a strategic repositioning of the industry. With a leadership team that values evidence-based policy and patient-centered innovation, the organization is prepared to meet the challenges of a rapidly evolving medical landscape. As the 2026–2027 term begins, the focus remains firmly on the goal of ensuring that every patient in Peru has access to the life-changing therapies of the future.
